Anonymous
Guest
Anonymous
Guest
Pretty much sums it up folks: (from Yahoo finance)
Shares of Questcor Pharmaceuticals (NASDAQ: QCOR ) tumbled on Thursday after Blue Cross Blue Shield Michigan became the latest company to hint at scaling back its coverage of Questcor's flagship Acthar Gel. The insurer came out against the treatment in all indications save for infantile spasm.
Questcor has responded to negative sentiment -- as health insurers and pharmacy benefit management companies scale back on coverage and bearish attacks -- through stock repurchases and initiating a dividend policy.
However, as more providers turn on reimbursing the costly gel treatment, Questcor will have to either prove itself or shave prices. It's not where Questcor would like to be these days.
Shares of Questcor Pharmaceuticals (NASDAQ: QCOR ) tumbled on Thursday after Blue Cross Blue Shield Michigan became the latest company to hint at scaling back its coverage of Questcor's flagship Acthar Gel. The insurer came out against the treatment in all indications save for infantile spasm.
Questcor has responded to negative sentiment -- as health insurers and pharmacy benefit management companies scale back on coverage and bearish attacks -- through stock repurchases and initiating a dividend policy.
However, as more providers turn on reimbursing the costly gel treatment, Questcor will have to either prove itself or shave prices. It's not where Questcor would like to be these days.